TScan Therapeutics, Inc.
TCRXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | downgrade | Buy →Neutral | Sep 8, 2026 |
| Wedbush | downgrade | Outperform →Neutral | Sep 3, 2026 |
| Needham | downgrade | Buy →Hold | Sep 2, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2026 |
| Wedbush | maintain | Outperform | Jun 23, 2026 |
| Needham | maintain | Buy | Jun 23, 2026 |
| Wedbush | maintain | Outperform | Mar 5, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2025 |
| BTIG | downgrade | Buy →Neutral | Nov 4, 2025 |
| Needham | maintain | Buy | Nov 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2025 |
| Needham | maintain | Buy | Apr 8, 2025 |
| Barclays | maintain | Overweight | Mar 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2025 |
| Needham | maintain | Buy | Mar 5, 2025 |
| Needham | maintain | Buy | Dec 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| Needham | maintain | Buy | Nov 12, 2024 |
| Needham | maintain | Buy | Nov 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2024 |
| Wedbush | maintain | Outperform | Aug 13, 2024 |
| Needham | maintain | Buy | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.18| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.23 | $-0.25 | $1.1M | $1.9M |
| May 6, 2026 | $-0.22 | $-0.22 | $982.0K | $2.5M |
| Mar 4, 2026 | $-0.18 | $-0.27 | $2.6M | $2.4M |
| Nov 12, 2025 | $-0.28 | $-0.35 | $2.5M | $1.9M |
| Aug 12, 2025 | $-0.28 | $-0.28 | $3.1M | $1.9M |
| May 6, 2025 | $-0.26 | $-0.28 | $2.2M | $1.1M |
| Mar 5, 2025 | $-0.29 | $-0.27 | $665.0K | $1.5M |
| Nov 12, 2024 | $-0.25 | $-0.28 | $1.0M | $1.2M |
News
BioNTech (NASDAQ: BNTX - Get Free Report) and TScan Therapeutics (NASDAQ: TCRX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Earnings and Valuation This table compares BioNTech and TScan
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%.
Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism Pauses further enrollment in Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital; allowing data to mature and actively seeking collaboration partners Workforce reduction of approximately 75% and strategic…
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.
First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapie…